A tetrahedral framework nucleic acid-NAP polypeptide complex and its use in preparing a drug for treating septic encephalitis

Through intranasal administration of tetrahedral framework nucleic acid and NAP polypeptide complex, the problems of neuronal protection and drug crossing the blood-brain barrier in the treatment of septic encephalitis were solved, achieving non-invasive and efficient treatment effects, significantly improving Symptoms of inflammation and cognitive dysfunction.

CN118178669BActive Publication Date: 2024-12-06SICHUAN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410294179.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-03-14
Publication Date
2024-12-06
Estimated Expiration
2044-03-14

AI Technical Summary

Technical Problem

The existing treatment methods for septic encephalitis ignore neuronal protection, and traditional administration methods are difficult to cross the blood-brain barrier, making it difficult for drugs to reach the brain effectively. Traditional administration methods are highly invasive and have many side effects. They are given through the nose. Although the drug has potential, its stability and release speed are uncontrollable.

Method used

Using tetrahedral framework nucleic acid and NAP polypeptide complex, a stable complex is formed through specific base pairing assembly to prepare drugs for the treatment of septic encephalitis, non-invasive treatment through intranasal administration, and reduce TNF- a. IL-6, IL-1β and other inflammatory factors are expressed, and have neuroprotective effects.

Benefits of technology

Significantly reduce the expression of inflammatory factors in brain tissue, improve the symptoms of cognitive dysfunction, dysdirection, drowsiness, confusion of consciousness, anxiety and other symptoms of septic encephalitis, provide new and effective treatment methods, reduce side effects, and improve treatment safety and patient compliance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118178669B_ABST
    Figure CN118178669B_ABST
Patent Text Reader

Abstract

The present invention provides a tetrahedral framework nucleic acid-NAP polypeptide complex and its use for preparing a drug for treating septic encephalitis. The tetrahedral framework nucleic acid-NAP polypeptide complex of the present invention can significantly reduce the expression of inflammatory factors such as TNF-a, IL-6, IL-1β in brain tissue, and also has a neuroprotective effect, and can significantly improve the cognitive dysfunction, disorientation, drowsiness, confusion, anxiety and other consciousness disorder symptoms of septic encephalitis, treat septic encephalitis, and prevent the sequelae of septic encephalitis. The tetrahedral framework nucleic acid-NAP polypeptide complex of the present invention can be administered by intranasal administration to achieve non-invasive treatment, reduce side effects, improve the safety of treatment and patient compliance, and provide a new and effective means for the clinical treatment of septic encephalitis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biomedicine, and in particular relates to a tetrahedral framework nucleic acid-NAP polypeptide complex and use thereof in preparing a medicine for treating septic encephalitis. Background Art

[0002] Septic encephalitis is an inflammatory disease of the brain caused by sepsis, and is a serious, life-threatening disease. Patients with septic encephalitis usually experience fever and chills, and may experience typical symptoms of encephalitis, such as drowsiness, confusion, decreased learning and memory, loss of interest in exploration, disorientation, anxiety, and other disturbances of consciousness, and even coma.

[0003] Existing treatments for septic encephalitis mainly focus on using antibiotics or other drugs to control infection. However, these methods ignore the protection of neurons and other nerve cells. This neglect leads to sequelae such as long-term neurological damage and impaired consciousness in patients with septic encephalitis. So far, there is no ideal treatment for septic encephalitis.

[0004] On the other hand, with the continuous innovation of clinical treatment technology, how to efficiently and accurately deliver drugs to brain tissue has become the focus of researchers. At present, the process of treating brain diseases is often significantly restricted by the blood-brain barrier. This natural blood-brain barrier mechanism is designed to protect the brain and ensure that harmful substances cannot enter, but it also makes it difficult for most drugs to reach the brain. Traditional drug delivery methods, such as epidural injections and spinal injections, have actually been known by the academic community as early as the early 20th century. These methods can deliver drugs directly to the brain or cerebrospinal fluid, but their application is still limited due to their invasiveness, potential complications, and patient acceptance.

[0005] In recent decades, nasal administration has received extensive attention and research as a new method of drug delivery. The principle of this method is relatively simple: through the nasal cavity, taking advantage of its special connection with the brain, the drug is delivered directly to the brain. It is worth noting that nasal administration has obvious advantages over other methods. For example, the olfactory epithelium in the nasal cavity has a direct neural connection with the brain, which allows drugs to enter the brain efficiently through the "nose-brain" pathway. In addition, this method is simple, painless, low-risk, and can bypass the first-pass effect of the liver to ensure rapid absorption and sustained effect of the drug. Although nasal administration has shown great therapeutic and application potential, it still faces many challenges in practical applications. For example, current research mainly uses various nano-delivery systems, such as liposomes, peptides, and polymers to improve the bioavailability of drugs. However, these systems also have problems such as insufficient stability and uncontrollable drug release rate.

[0006] The latest research has begun to explore the use of DNA tetrahedral framework nucleic acid (TFNA) as a drug delivery carrier. This new type of carrier is composed of four nucleic acid single strands that are autonomously assembled through specific base pairing. It has excellent biocompatibility and stability, and can be customized to carry different drug molecules as needed.

[0007] NAP polypeptide specifically refers to a polypeptide composed of eight amino acids derived from the active domain of activity-dependent neuroprotective protein (ADNP), with a molecular weight of 824Da and an amino acid sequence of SEQ ID NO.1: NAPVSIPQ. CN108685875B A natural nanoparticle-drug composition for treating Alzheimer's disease, a preparation method and application thereof, discloses that NAP polypeptide can be used to treat Alzheimer's disease.

[0008] There are currently no reports on the use of TFNA combined with NAP peptide to treat septic encephalitis. Summary of the invention

[0009] The object of the present invention is to provide a tetrahedral framework nucleic acid-NAP polypeptide complex and use thereof in preparing a medicine for treating septic encephalitis.

[0010] The invention provides a tetrahedral framework nucleic acid-NAP polypeptide complex, which is a complex composed of a DNA tetrahedral framework nucleic acid and a NAP polypeptide; the molar ratio of the DNA tetrahedral framework nucleic acid to the NAP polypeptide is 1:(1-6).

[0011] Furthermore, the molar ratio of the DNA tetrahedral framework nucleic acid to the NAP polypeptide is 1:1.

[0012] Furthermore, the DNA tetrahedral framework nucleic acid is formed by base complementary pairing of four single-stranded DNA molecules whose sequences are shown in SEQ ID NO.2, SEQ ID NO.3, SEQ ID NO.5 and SEQ ID NO.6 respectively; and / or, the amino acid sequence of the NAP polypeptide is shown in SEQ ID NO.1.

[0013] The present invention also provides a method for preparing the above-mentioned complex, comprising dissolving four single-stranded DNAs with sequences such as SEQ ID NO.2, SEQ ID NO.3, SEQ ID NO.5 and SEQ ID NO.6 and a NAP polypeptide connected with gggttgttgg in a buffer solution and incubating them together to obtain the complex.

[0014] Furthermore, the co-incubation temperature is 60-95° C. and maintained for 0.1-10 h, and then cooled to 3-6° C. and maintained for 0.1-10 h.

[0015] Furthermore, the four single-stranded DNAs and the NAP polypeptide connected with gggttgttgg were dissolved in TM buffer, kept at 70° C. for 10 minutes, and then cooled to 4° C. and kept for 20 minutes.

[0016] The present invention also provides a drug for treating septic encephalitis and / or preventing sequelae of septic encephalitis, which is prepared by using the complex described in any one of claims 1 to 3 as an active ingredient and adding pharmaceutically acceptable excipients.

[0017] The present invention also provides the use of the above-mentioned complex in preparing a drug for treating encephalitis and / or preventing sequelae of septic encephalitis.

[0018] Furthermore, the encephalitis is septic encephalitis.

[0019] Furthermore, the drug is a drug that reduces the expression of inflammatory factors such as TNF-a, IL-6, and IL-1β in brain tissue; and / or the drug is a drug that improves consciousness disorder in septic encephalitis. Preferably, the consciousness disorder is cognitive dysfunction, and / or disorientation, and / or drowsiness, and / or confusion, and / or anxiety.

[0020] In summary, the present invention provides a tetrahedral framework nucleic acid-NAP polypeptide complex and its use for preparing a drug for treating septic encephalitis. The tetrahedral framework nucleic acid-NAP polypeptide complex of the present invention can significantly reduce the expression of inflammatory factors such as TNF-a, IL-6, IL-1β, and can effectively inhibit brain tissue inflammation. It also has a neuroprotective effect and can significantly improve the cognitive dysfunction, disorientation, drowsiness, confusion, anxiety and other consciousness disorder symptoms of septic encephalitis, and can treat septic encephalitis and prevent sequelae of septic encephalitis. At the same time, the present invention realizes non-invasive treatment through intranasal administration, reduces side effects, improves the safety of treatment and patient compliance, and provides a new and effective means for the clinical treatment of septic encephalitis.

[0021] Obviously, according to the above contents of the present invention, in accordance with common technical knowledge and customary means in the art, without departing from the above basic technical ideas of the present invention, other various forms of modification, replacement or change may be made.

[0022] The above contents of the present invention are further described in detail below through specific implementation methods in the form of embodiments. However, this should not be understood as the scope of the above subject matter of the present invention being limited to the following examples. All technologies realized based on the above contents of the present invention belong to the scope of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1The PAGE gel electrophoresis results of TFNA-Cy5, NAP-Tamra-TFNA-Cy5, and NAP-Tamra indicate the successful synthesis of the complex.

[0024] Figure 2 This is the transmission electron microscopy result of NAP-TFNA.

[0025] Figure 3 This is the dynamic light scattering result of NAP-TFNA. It can be seen that the particle size of NAP-TFNA is 11.25 nm and is negatively charged.

[0026] Figure 4 Atomic force microscopy results of NAP-TFNA.

[0027] Figure 5 The transcription results of TNF-a(A), IL-1b(B), IL-6(C), and iNOS(D) in each group.

[0028] Figure 6 A is the NO release of each group after 24 hours, and B is the NO release of each group after 48 hours.

[0029] Figure 7 Shown are the WB test results of inflammation-related proteins in each group.

[0030] Figure 8 The results of immunofluorescence staining show that in BV2 cells, NAP-TFNA can reduce the expression of LPS-induced IL-1β protein during inflammation.

[0031] Fig. 9 The results of immunofluorescence staining show that in BV2 cells, NAP-TFNA can reduce the expression of LPS-induced IL-6 protein during inflammation.

[0032] Fig.10 The results of immunofluorescence staining show that in BV2 cells, NAP-TFNA can reduce the expression of LPS-induced TNF-a protein during inflammation.

[0033] Fig.11 Results of the open field test: (A) the time the mouse stayed in the corner, (B) the total distance the mouse moved, and (C) the trajectory of the mouse's movement in the open field. This indicates that tetrahedrons loaded with peptides can be delivered into the brain through the nose to improve the cognitive ability of mice in an inflammatory state after LPS treatment.

[0034] Fig.12The results of the mouse water maze experiment, (A) the movement trajectory of the mouse in the maze, (B) the total movement distance of the mouse in the maze, (C) the orientation angle, and (D) the escape latency. This indicates that the tetrahedron carrying the peptide can be delivered into the brain through the nose to improve the cognitive ability of mice in the inflammatory state after LPS treatment.

[0035] Fig.13 The results of the Y-maze experiment are shown in Figure 1. (A) The percentage of exploring the new arm, and (B) The time spent in the new arm. This indicates that the tetrahedron carrying the peptide can be delivered into the brain through the nose to improve the memory and learning ability of mice in the inflammatory state after LPS treatment.

[0036] Fig.14 The results of the novel object recognition experiment are shown in Figure 1. (A) The number of explorations of new and old objects, and (B) the recognition index. This indicates that tetrahedrons loaded with peptides can be delivered into the brain through the nose to improve the memory and learning ability of mice in an inflammatory state after LPS treatment.

[0037] Fig.15 The following are the results of q-PCR detection of inflammatory factor transcription, including the transcription results of TNF-a (A), IL-1b (B), and IL-6 (C).

[0038] Fig.16 The results of WB detection of inflammation-related protein expression show that the TFNA-NAP polypeptide complex can effectively inhibit brain tissue inflammation.

[0039] Fig.17 This is the result of immunofluorescence staining of microglia activation. It can be seen from the figure that the TFNA-NAP polypeptide complex can inhibit the activation of microglia in the body after being introduced into the brain through the nose.

[0040] Fig.18 This is the result of Nissl body staining. DETAILED DESCRIPTION

[0041] The raw materials and equipment used in the present invention are all known products, which are obtained by purchasing commercially available products.

[0042] Example 1. Synthesis and characterization of tetrahedral framework nucleic acid-NAP polypeptide complex

[0043] 1. Experimental Methods

[0044] (I) Synthesis of tetrahedral framework nucleic acid-NAP polypeptide complex (NAP-TFNA complex)

[0045] 1. Preparation of AT-NAP

[0046] In order to connect the NAP polypeptide to the tetrahedral framework nucleic acid, the basic structure of the NAP polypeptide was modified to obtain NAP-Pra. The polypeptide sequence is NAPVSIPQ-Pra. NAPVSIPQ-Pra is modified with an alkynyl group at the end of the NAP polypeptide. The modified NAPVSIPQ-Pra was ordered from Guopeptide Biotechnology. NAPVSIPQ-Pra carries a Tamra fluorescent group.

[0047] The sticky end chain gggttgttgg and NAP-Pra were connected together by click chemistry to form AT-NAP. One part of vitamin C (10mM), one part of copper sulfate (10mM), 2.986 parts of DMSO, and 0.354 parts of TBTA (28.3Mm) were added to the centrifuge tube in sequence, and allowed to stand overnight. One part of gggttgttgg (200uM) and 0.66 parts of NAP-Pra (600uM) were added to complete the click.

[0048] 2. Preparation of NAP-TFNA

[0049] Table 1 Single-stranded DNA sequences of the present invention

[0050]

[0051] Four DNA single strands S1, S2, AT-S3-8, S4 and AT-NAP-Pra were added to TM buffer (10mM Tris-HCl and 50mM MgCl2 dissolved in water, and the pH value was adjusted to 8.0 with hydrochloric acid) in an equimolar ratio. The final concentration of the four DNA single strands and AT-NAP-Pra was 1μM. The DNA single strands were heated at 70℃ for 10 minutes to unfold and reorganize into a tetrahedral structure, and the sticky ends were complementary paired. Then, the DNA was quickly cooled to 4℃ and maintained for 20 minutes to reorganize the DNA to obtain a tetrahedral framework nucleic acid-NAP polypeptide complex, named NAP-TFNA. The molar ratio of TFNA and NAP polypeptide in the NAP-TFNA complex was 1:1.

[0052] Comparative Example 1: Preparation of Tetrahedral Framework Nucleic Acid TFNA

[0053] Equimolar amounts of four DNA single strands S1, S2, S3, and S4 (the final concentrations of the four DNA single strands after dissolution were all 1 μM) were dissolved in TM buffer (50 mM MgCl2 and 10 mM TrisHCl, pH 8.0), heated to 95°C for 10 min, and then rapidly cooled to 4°C for more than 20 min to allow DNA recombination, thereby synthesizing tetrahedral framework nucleic acids (TFNAs).

[0054] The beneficial effects of the NAP-TFNA complex prepared in Example 1 of the present invention are demonstrated below through specific test examples.

[0055] Experimental Example 1: Characterization of NAP-TFNA complex

[0056] 1. Experimental Methods

[0057] The morphological information of tetrahedral framework nucleic acids was obtained through PAGE gel electrophoresis, transmission electron microscopy, dynamic light scattering, and atomic force microscopy.

[0058] 1. PAGE gel electrophoresis

[0059] The successful synthesis of NAP-TFNA complex was verified by PAGE. After the glass plate was leak-checked, 8% PAGE gel solution was added to the sample loading tank, and the comb was inserted and waited for the gel to solidify. TFNA and NAP-TFNA were mixed with the loading buffer and added to the sample loading tank, and electrophoresis was completed in a 1x TAE solution environment. The nucleic acid gel was then developed under a chemiluminescence imager. TFNA carries cy5 fluorescence, and NAP polypeptide carries Tamra fluorescence.

[0060] 2. Transmission electron microscopy

[0061] After 1 μM NAP-TFNA was diluted to 100 nM using TM buffer, a small amount of the sample was slowly dripped onto the copper grid. After re-staining for 3 minutes, the morphology of NAP-TFNA was determined by transmission electron microscopy.

[0062] 3. Dynamic Light Scattering

[0063] NAP-TFNA was diluted to 125 nM with TM buffer, and 1 mL of the sample was added to a potential dish and a particle size dish respectively, and both were placed in a potential particle size analyzer for detection and data analysis.

[0064] 4. Atomic force microscopy

[0065] After NAP-TFNA was diluted to 10 nM in TM buffer, 20 μL of the sample was transferred onto a freshly cut mica sheet. The droplet was left to adsorb on the mica surface for 15 minutes. The morphology of NAP-TFNA was measured by AFM using tapping mode.

[0066] 2. Experimental Results

[0067] 1. PAGE gel electrophoresis

[0068] PAGE gel electrophoresis results are as follows Figure 1 As shown, it can be seen that the three bands are at different positions in the picture, indicating that NAP-TFNA was successfully synthesized.

[0069] 2. Transmission electron microscopy

[0070] Figure 2This is the transmission electron microscopy result of NAP-TFNA. It can be seen from the figure that the white NAP-TFNA is evenly distributed in the dark gray background medium.

[0071] 3. Dynamic Light Scattering

[0072] Figure 3 The dynamic light scattering results of NAP-TFNA show that the particle size of NAP-TFNA is 11.25 nm and it is negatively charged.

[0073] 4. Atomic force microscopy

[0074] Figure 4 This is the atomic force microscopy result of NAP-TFNA. It can be seen from the figure that the high-density ones are NAP-TFNA nanoparticles. According to the scale, their size is about 15-20nm. The microscope imaging will be slightly magnified.

[0075] The experimental results showed that NAP-TFNA was successfully synthesized.

[0076] Experimental Example 2: Cell Experiment

[0077] I. Experimental methods (I) NAP-TFNA complex can regulate the inflammatory state of microglia in vitro 1. Experimental groups

[0078] The present invention uses BV2 cells, which are a mouse microglial cell line and are commonly used in neuroscience research. The present invention uses lipopolysaccharide (LPS) and BV2 cells to construct an inflammatory microglial cell model. It is maintained in DMEM / F-12 culture medium (Gibco, 11320033) containing 10% fetal bovine serum (Biochannel, BC-SE-FBS01), 0.5% (v:v) penicillin / streptomycin (Gibco, 35050061), and cultured at 37°C in a 5% carbon dioxide humidified atmosphere. The medium is replaced with serum-free medium 4 hours before modeling.

[0079] BV2 cells were divided into 5 groups:

[0080] Blank group: BV2 cells were cultured in serum-free medium only without LPS or other drugs.

[0081] LPS group: BV2 cells were cultured in serum-free medium containing LPS at a final concentration of 1 mg / ml;

[0082] LPS+TFNA group: BV2 cells were cultured in serum-free medium containing LPS at a final concentration of 1 mg / ml and tFNA at a final concentration of 300 nM.

[0083] LPS+NAP group: BV2 cells were cultured in serum-free medium containing LPS at a final concentration of 1 mg / ml and NAP at a final concentration of 300 nM.

[0084] LPS+NAP-TFNA group: BV2 cells were cultured in serum-free medium containing LPS at a final concentration of 1 mg / ml and NAP-TFNA at a final concentration of 300 nM.

[0085] 2. Inspection method

[0086] 1) After 6 hours of culture, BV2 cells were collected and intracellular RNA was extracted using a total RNA extraction kit. After reverse transcription into cDNA, RT-qPCR technology was used to detect the transcription of intracellular inflammatory factors.

[0087] 2) After culturing for 24 and 48 hours, the supernatant of BV2 cells in each group was collected and the NO release was detected using a NO detection kit.

[0088] 3) After 24 hours of culture, BV2 cells were collected, and all proteins in the cells were extracted using a protein extraction kit. Western blotting was used to detect the expression of inflammation-related proteins.

[0089] 4) After 24 hours of culture, BV2 cells were fixed with paraformaldehyde and immunofluorescence staining was performed to illustrate the distribution of inflammation-related proteins in the cells.

[0090] 2. Experimental Results

[0091] 1. qPCR test results

[0092] Figure 5 The results of the transcription of inflammatory factors TNF-a, IL-1b, IL-6, and iNOS in each group show that the transcription of each inflammatory factor in the LPS group was significantly higher than that in the blank control group, indicating that the inflammatory microglial cell model was successfully constructed. The figure shows that the transcription of each inflammatory factor in the LPS+NAP group, LPS+TFNA group, and LPS+NAP-TFNA group was significantly lower than that in the LPS group, among which the inflammatory factors in the LPS+NAP-TFNA group were most significantly reduced. The experimental results show that NAP-TFNA can significantly reduce the transcription of inflammatory factors TNF-a, IL-1b, IL-6, and iNOS in LPS-induced BV2 cells, especially IL-1b.

[0093] 2. NO release test results

[0094] Figure 6 This indicates that NAP-TFNA can reduce LPS-induced NO release in BV2 cells. Figure 6 A and Figure 6As shown in B, it can be seen that the NO release in the LPS group was the highest, indicating that the microglia in the inflammatory model were successfully constructed. Except for the blank control group, the NO release in the NAP-TFNA group was the lowest, significantly lower than that in the LPS+NAP group and the LPS+TFNA group. The experimental results show that NAP-TFNA can significantly reduce the NO release induced by LPS.

[0095] 3. WB test results

[0096] Figure 7 The WB test results of inflammation-related proteins in each group. It can be seen from the figure that in BV2 cells, NAP-TFNA can reduce the expression of LPS-induced inflammation-related proteins during the inflammation process.

[0097] 4. Immunofluorescence staining results

[0098] Figure 8 This indicates that in BV2 cells, the addition of LPS can increase the expression of inflammatory protein IL-1β, indicating that the microglial inflammation model was successfully constructed. Except for the blank control group, the expression of IL-1β in the NAP-TFNA group was the lowest, significantly lower than that in the LPS+NAP group and the LPS+TFNA group. This indicates that NAP-TFNA can reduce the expression of LPS-induced IL-1β protein during inflammation.

[0099] Fig. 9 This indicates that in BV2 cells, the addition of LPS can increase the expression of inflammatory protein IL-6, indicating that the microglial inflammation model was successfully constructed. Except for the blank control group, the expression of IL-6 in the NAP-TFNA group was the lowest, significantly lower than that in the LPS+NAP group and the LPS+TFNA group. This indicates that NAP-TFNA can reduce the expression of LPS-induced IL-6 protein during inflammation.

[0100] Fig.10 This indicates that in BV2 cells, the addition of LPS can increase the expression of inflammatory protein TNF-a, indicating that the microglial inflammation model was successfully constructed. Except for the blank control group, the expression of TNF-a in the NAP-TFNA group was the lowest, significantly lower than that in the LPS+NAP group and the LPS+TFNA group. This indicates that NAP-TFNA can reduce the expression of TNF-a protein induced by LPS during inflammation.

[0101] Experimental Example 3: Animal Experiment

[0102] 1. Experimental Methods

[0103] (I) Animal modeling and grouping

[0104] LPS is currently recognized as a modeling method for constructing a sepsis model. The clinical manifestations of septic encephalitis are impaired consciousness, specifically anxious stress reactions, decreased learning and memory abilities, and decreased interest in exploration. The present invention uses LPS to construct septic mice, and the behavioral experiments of mice and the significant increase in the mRNA expression of inflammatory factors in brain tissue prove that the animal model of septic encephalitis is successfully constructed. LPS was purchased from Sigma (USA).

[0105] 6-8 week old male Balb / c mice were randomly divided into 5 groups, 12 mice in each group, and the following operations were performed:

[0106] LPS group: LPS (5 mg / kg) was injected intraperitoneally, and 25 μl of normal saline was dripped into the nasal cavity 1 hour later;

[0107] LPS+TFNA group: LPS (5 mg / kg) was injected intraperitoneally, and 25 μl of normal saline containing 1 μM TFNA was dripped into the nasal cavity 1 hour later;

[0108] LPS+NAP group: LPS (5 mg / kg) was injected intraperitoneally. One hour later, 25 ul of normal saline containing 1 μM NAP was dripped into the nasal cavity:

[0109] LPS+NAP-TFNA group: LPS (5 mg / kg) was injected intraperitoneally. One hour later, 25 ul of normal saline containing 1 μM NAP-TFNA was dripped into the nasal cavity:

[0110] Blank group: The same volume of normal saline as that of LPS group was injected into the peritoneal cavity, and 25ul of normal saline was dripped into the nasal cavity.

[0111] (II) Behavioral experiments on experimental mice

[0112] The clinical manifestations of septic encephalitis are impaired consciousness, specifically anxious stress response, decreased learning and memory ability, and decreased interest in exploration. The present invention uses open field test, mouse water maze test and Y maze test to detect the effect of NAP-TFNA on mice with septic encephalitis.

[0113] 1. Open field experiment

[0114] The open field test is commonly used to assess exploratory behavior, activity level, and anxiety in mice.

[0115] 23 hours after administration, 3 mice were randomly selected from each group for an open field test. An open square or circular field with transparent or opaque walls around it was prepared to observe the behavior of the mice. Each group of mice was placed in the center of the open field box and allowed to freely explore the environment for 5 minutes. At the same time, the behavioral parameters of the mice were recorded using the Rayward behavioral recording and analysis software, such as the time spent on the side wall, the total distance moved in the open field, the trajectory of movement in the open field, etc., and the behavioral data of the mice were statistically analyzed.

[0116] 2. Mouse water maze experiment

[0117] The water maze test is a widely used method to assess the learning, memory and spatial navigation abilities of mice.

[0118] 23 hours after administration, except for the mice in the open field experiment, 3 mice were randomly selected from each group of the remaining mice for a water maze experiment. Before the water maze experiment began, a circular pool was prepared. Enough water was added to the pool so that the mice in each group could not touch the bottom. The water was dyed to cover the position of the underwater platform. An invisible platform was placed in a fixed position under the water surface. Each group of mice needed to learn and remember the position of this platform in order to escape from the water. During the training phase, each group of mice was placed at different starting points in the water maze and learned to find the hidden platform through visual cues. During the training process, the motion trajectory of each group of mice when entering the water, the total distance moved in the water maze, the time required to find the escape platform, and the orientation angle statistics after the water were recorded using the Rayward behavioral recording and analysis software to evaluate their learning and memory abilities.

[0119] 3. Y-maze experiment

[0120] 23 hours after administration, 3 mice were randomly selected from each group except for the mice in the open field test and water maze test to perform the Y maze test.

[0121] A maze with three identical arms (8 × 18 × 38 cm) was used. At the beginning of the test, the mouse was placed in the middle of the maze, a door was placed in front of one of the arms to block the mouse from entering, and the mouse was allowed to explore for 5 minutes. After one hour, the door blocking the arm was removed and free exploration was allowed again for 5 minutes. In this test, the number of spontaneous alternations and the number of entries into the arm were recorded using the Rayward behavioral recording and analysis software.

[0122] 4. New object recognition experiment

[0123] The novel object recognition test is used to evaluate the learning and memory ability of mice. 23 hours after administration, the remaining 3 mice in each group were subjected to the novel object recognition test.

[0124] The same field as the open field experiment was used to prepare three objects, A, B, and C (with an average diameter of about 3 cm). Objects A and B were exactly the same, while object C was very different from objects A and B. The experiment was divided into three stages: adaptation, familiarization, and testing. During the adaptation stage, no objects were placed in the field, and mice were allowed to move freely. During the familiarization stage, objects A and B were placed in the field, and the time and number of explorations of the objects by the mice within 5 minutes were recorded (the exploration of the objects was counted as touching the objects with the mouth or nose and approaching the objects within a range of about 2-3 cm); during the testing stage, object B was replaced with object C after an interval of 1 hour from the previous stage, and mice were placed in the field. The time and number of explorations of the objects by the mice within 5 minutes were recorded using the Rayward behavioral recording and analysis software. The time each mouse spent exploring the new object, T1, and the time each mouse spent exploring the old object, T2, were used to calculate the cognitive index RI = T1 / (T1+T2) for each mouse.

[0125] (III) Brain tissue detection methods

[0126] 1. Brain tissue inflammation detection

[0127] (1) q-PCR detection of inflammatory factor secretion

[0128] After the mouse behavior experiment, brain tissues of 3 mice in each group were randomly collected and homogenized, and RNA was extracted using an RNA extraction kit for qPCR detection of the expression of inflammation-related genes.

[0129] (2) WB detection of inflammatory factor secretion

[0130] After the mouse behavior experiment, brain tissues of 3 mice in each group of the remaining mice were randomly collected and homogenized. RNA was extracted using a protein extraction kit for qPCR detection of the expression of inflammation-related genes, and proteins were collected for WB detection of the expression of inflammatory proteins.

[0131] 2. Brain tissue staining results

[0132] After the mouse behavior experiment, brain tissues of 3 mice in each group of the remaining mice were randomly collected, fixed, sliced ​​and stained to observe the activation of microglia and the number of Nissl bodies. The results showed the protection against BV2 activation in brain tissue.

[0133] 2. Experimental results (I) Behavioral test results of experimental mice

[0134] 1. Open field experiment

[0135] The results of the open field test are as follows Fig.11 As shown, Fig.11A is the time the mice stayed on the side wall. It can be seen that the mice in the LPS group tended to stick to the wall compared with the blank group, indicating that the septic encephalitis mouse modeling was successful. There was no significant difference in the sticking time of the mice in the LPS+NAP and LPS+TFNA groups compared with the LPS group, while the sticking time of the mice in the NAP-TFNA group was significantly reduced compared with the LPS group, LPS+NAP and LPS+TFNA mice.

[0136] Fig.11 B is the total distance that mice moved in the open field. It can be seen that the total distance that mice in the LPS group moved in the open field was significantly reduced compared with the blank group. The total distance that mice in the LPS+NAP and LPS+TFNA groups moved in the open field increased slightly, while the total distance that mice in the NAP-TFNA group moved in the open field was significantly increased compared with the LPS group, LPS+NAP and LPS+TFNA mice.

[0137] Fig.11 C is the trajectory of the mouse moving in the open field.

[0138] The experimental results showed that NAP-TFNA can significantly improve the exploratory behavior, activity level and anxiety of model mice, and can effectively improve the symptoms of consciousness disorders such as drowsiness, confusion, anxiety, etc. in septic encephalitis.

[0139] 2. Mouse water maze experiment

[0140] The results of the water maze test were as follows Fig.12 As shown, Fig.12 A is a heat map of the movement trajectory of mice in the water maze. It can be seen that the mice in the LPS group tended to spin in place, and their motor and memory abilities were impaired, indicating that the septic encephalitis mouse model was successfully established.

[0141] Fig.12 B is the total distance moved by mice in the water maze. The total distance moved by mice in the blank group in the water maze was short because they found the escape platform in time. The total distance moved by mice in the LPS group in the water maze was short because they tended to go around in circles and did not find the escape platform. The total distance moved by mice in the NAP-TFNA group was significantly increased compared with that in the LPS group, and they were able to find the escape platform.

[0142] Fig.12 C is the statistic of the orientation angle of the mouse after entering the water, Fig.12 D is the total time statistics for mice to find the escape platform. The water maze experiment was recorded for 1 minute. The mice in the LPS group, NAP group, and TFNA group did not find the escape platform, and the software automatically stopped timing. Therefore, the total time for the LPS group, NAP group, and TFNA group was 60 seconds. The mice in the NAP-TFNA group could quickly find the escape platform in the maze.

[0143] The experimental results showed that NAP-TFNA can significantly improve the learning, memory and spatial navigation abilities of model mice, and NAP-TFNA can effectively improve the symptoms of consciousness disorders such as disorientation and cognitive dysfunction in septic encephalitis.

[0144] (3) Y-maze test

[0145] The statistical results of the Y-maze experiment are as follows Fig.13 As shown, it can be seen that the exploration ability of mice in the LPS group to the new arm decreased, indicating that the septic encephalitis mouse model was successfully established.

[0146] Fig.13 A counted the proportion of mice exploring the new arm. The proportion of mice in the LPS group exploring the new arm decreased significantly, the proportion of mice in the NAP and TFNA groups exploring the new arm increased slightly compared with the LPS group, and the proportion of mice in the NAP-TFNA group exploring the new arm increased significantly compared with the LPS group.

[0147] Fig.13 B. The time that mice stayed in the new arm was counted. The time that mice in the LPS group stayed in the new arm was significantly decreased. The time that mice in the NAP group, TFNA group, and NAP-TFNA group stayed in the new arm was increased compared with that in the LPS group, and the increase in the NAP-TFNA group was the most significant.

[0148] The experimental results showed that NAP-TFNA can be administered through the nose into the brain to improve the cognitive ability of model mice and can improve the symptoms of cognitive dysfunction and consciousness disorders in septic encephalitis.

[0149] (4) New object recognition experiment

[0150] The experimental results of new object recognition are as follows Fig.14 As shown, the ability of mice to explore new objects decreased after LPS modeling, indicating that the septic encephalitis mice were successfully constructed.

[0151] Fig.14 A counted the number of times the mice explored new and old objects. The number of times the mice in the LPS group explored new objects decreased significantly, and the number of times the mice in the NAP group, TFNA group, and NAP-TFNA group explored new objects increased compared with the LPS group. However, the increase in the number of times the mice in the NAP group and TFNA group explored new objects was not obvious. Only the number of times the mice in the NAP-TFNA group explored new objects increased significantly compared with the LPS group.

[0152] Fig.14B. The mice's ability to recognize old objects was statistically analyzed. The recognition ability of mice in the LPS group was significantly decreased, while the recognition ability of mice in the NAP group, TFNA group and NAP-TFNA group was improved, and the recognition ability of mice in the NAP-TFNA group was most significantly improved. NAP-TFNA significantly increased the recognition ability of mice with septic encephalitis to old objects.

[0153] The experimental results show that NAP-TFNA can be administered through the nose into the brain to improve the memory, learning and recognition abilities of model mice, and NAP-TFNA can effectively improve cognitive dysfunction in septic encephalitis.

[0154] The experimental results show that NAP-TFNA can improve the symptoms of cognitive dysfunction, disorientation, drowsiness, confusion, anxiety and other consciousness disorders in septic encephalitis, and can treat septic encephalitis and prevent the sequelae of septic encephalitis.

[0155] (II) Brain tissue inflammation detection

[0156] 1. q-PCR detection of inflammatory factor transcription

[0157] Fig.15 The results of q-PCR detection of inflammatory factors in each group are shown in Figure 1. TNF-a ( Fig.15 A), IL-1b( Fig.15 B), IL-6 ( Fig.15 C) The transcription results showed that the expressions of inflammatory factors TNF-a mRNA, IL-1b mRNA and IL-6 mRNA in the brain tissue of mice in the LPS group were significantly increased, indicating that the septic encephalitis mouse model was successfully established.

[0158] At the same time from Fig.15 It can be seen that NAP-TFNA can significantly reduce the transcription of factors TNF-a, IL-1b, IL-6, especially IL-1b and IL-6. It can be seen that NAP and TFNA in NAP-TFNA have a synergistic effect, and the transcription of inflammatory factors is significantly reduced. The experimental results show that NAP-TFNA can effectively inhibit brain tissue inflammation in mice with septic encephalitis.

[0159] 2. WB detection of inflammatory factor secretion

[0160] WB detection of inflammatory factors secretion Fig.16 As shown, the results showed that TFNA-NAP could effectively inhibit the expression of inflammatory proteins in brain tissue, such as TNF-a, IL-6, IL-1β, etc., and significantly reduced the proportion of P65 phosphorylation.

[0161] 3. Brain tissue staining results

[0162] (1) Immunofluorescence staining results of brain microglial activation

[0163] Immunofluorescence staining results of brain microglial activation Fig.17 As shown in Figure 13A, it can be seen that after LPS stimulation, microglia showed a polarized response, with more antennae and thicker cells, while microglia in the NAP-TFNA group were in a quiescent state.

[0164] Fig.17 B. Fig.17 C counted the number and fluorescence intensity of microglia per unit area. It can be seen that the number of microglia in the LPS group mice increased significantly compared with that in the blank group, indicating that the septic encephalitis mice were successfully constructed. The number of microglia in the NAP group, TFNA group and NAP-TFNA group was inhibited compared with that in the LPS group and NAP-TFNA group, and the number of microglia in the NAP-TFNA group was most significant. The number of microglia in the NAP-TFNA group was significantly lower than that in the LPS group, NAP group and TFNA group.

[0165] The experimental results showed that NAP and TFNA have a synergistic effect, and NAP-TFNA can significantly inhibit the activation of microglia in septic encephalitis after being injected into the brain through the nose.

[0166] (2) Nissl body staining results

[0167] Nissl body staining results Fig.18 As shown, it can be seen that the size of neurons in the blank group is consistent and they have obvious cytoplasmic processes. The number of neurons in the brain tissue of the LPS group mice is significantly reduced compared to the blank group, and the neurons have lost their normal cytoplasmic processes. Compared with the LPS group, the TFNA, NAP and NAP-TFNA groups can improve the loss and damage of neurons, and NAP-TFNA is the most obvious. The experimental results show that NAP-TFNA can improve the loss and damage of neurons after being injected into the brain through the nose.

[0168] The experimental results showed that the NAP-TFNA complex can significantly reduce the expression of inflammatory factors such as TNF-a, IL-6, IL-1β, effectively inhibit brain tissue inflammation, and also has a neuroprotective effect, and can significantly improve the symptoms of impaired consciousness in mice with septic encephalitis.

[0169] In summary, the present invention provides a tetrahedral framework nucleic acid-NAP polypeptide complex and its use for preparing a drug for treating septic encephalitis. The tetrahedral framework nucleic acid-NAP polypeptide complex of the present invention can significantly reduce the expression of inflammatory factors such as TNF-a, IL-6, IL-1β, and can effectively inhibit brain tissue inflammation. It also has a neuroprotective effect and can significantly improve the cognitive dysfunction, disorientation, drowsiness, confusion, anxiety and other consciousness disorder symptoms of septic encephalitis, and can treat septic encephalitis and prevent sequelae of septic encephalitis. At the same time, the present invention realizes non-invasive treatment through intranasal administration, reduces side effects, improves the safety of treatment and patient compliance, and provides a new and effective means for the clinical treatment of septic encephalitis.

Claims

1. A tetrahedral framework nucleic acid-NAP polypeptide complex for treating septic encephalitis and / or preventing sequelae of septic encephalitis, characterized in that: It is a complex composed of a DNA tetrahedral framework nucleic acid formed by base complementary pairing of four single-stranded DNA molecules with sequences as shown in SEQ ID NO.2, SEQ ID NO.3, SEQ ID NO.5 and SEQ ID NO.6, and a NAP polypeptide with an amino acid sequence as shown in SEQ ID NO.1; the molar ratio of the DNA tetrahedral framework nucleic acid to the NAP polypeptide is 1:(1-6).

2. The composite according to claim 1, characterized in that The molar ratio of the DNA tetrahedral framework nucleic acid to the NAP polypeptide is 1:

1.

3. The method for preparing the composite according to any one of claims 1 to 2, characterized in that: The sequence is as SEQ ID The four single-stranded DNAs shown in SEQ ID NO.2, SEQ ID NO.3, SEQ ID NO.5 and SEQ ID NO.6 and the NAP polypeptide connected with gggttgttgg are dissolved in a buffer solution and incubated together to obtain the product.

4. The preparation method according to claim 3, characterized in that: The co-incubation temperature is 60-95° C. and maintained for 0.1-10 h, and then cooled to 3-6° C. and maintained for 0.1-10 h.

5. The preparation method according to claim 3, characterized in that: The four single-stranded DNAs and the NAP polypeptide connected with gggttgttgg were dissolved in TM buffer, kept at 70°C for 10 minutes, and then cooled to 4°C and kept for 20 minutes.

6. A drug for treating septic encephalitis and / or preventing sequelae of septic encephalitis, characterized in that: The invention is a medicine prepared by taking the complex described in any one of claims 1 to 2 as an active ingredient and adding pharmaceutically acceptable auxiliary materials.

7. Use of the complex according to any one of claims 1 to 2 in the preparation of a medicament for treating septic encephalitis and / or preventing sequelae of septic encephalitis.

8. The use according to claim 7, characterized in that The drug is a drug that reduces the expression of inflammatory factors such as TNF-a, IL-6, and IL-1β in brain tissue; and / or the drug is a drug that improves consciousness disorders caused by septic encephalitis.

9. The use according to claim 8, characterized in that The consciousness disorder is cognitive dysfunction, and / or disorientation, and / or drowsiness, and / or confusion, and / or anxiety.